Faculty

Back to Index
Todd A. Alonzo, PhD
Professor of Research Preventive Medicine
Group Statistician For Children's Oncology Group
Preventive Medicine
Children's Oncology Group Health Sciences Campus Monrovia
+1 626 241 1522

Overview

Todd Alonzo is a Professor of Research in the Department of Preventive Medicine, University of Southern California. He received his undergraduate degree at the California State Polytechnic University, San Luis Obispo, California in Statistics in 1994 and received both his MS and his PhD in Biostatistics in 1997 and 2000 from the University of Washington, Seattle. Dr. Alonzo’s main areas of research interest are the statistical methods for analysis of biomarkers and medical diagnostic and screening tests, clinical trials, and the design and analysis of pediatric acute myelogenous leukemia studies. He has published over 115 peer-reviewed articles including 18 as first author and written two book chapters. Dr. Alonzo has been member of the Editorial Board for Biometrics, Pediatric Blood Cancer, and Biometrical Journal and has acted as a reviewer for 30 scientific journals. He is also a member of several Data Safety and Monitoring Boards. Dr. Alonzo was the President of the International Biometric Society Western Northern America Region (WNAR) in 2009.

Awards

University of Washington: • Senior Biostatistics Award, Department of Biostatistics, 2000

• ENAR Biometrics Society Distinguished Student Paper Award

• WNAR Biometrics Society Best Student Oral Presentation

NIH: Predoctoral Cardiovascular Biostatistics Training Grant, 1995

Publications

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. J Clin Oncol. 2017 Sep 10; 35(26):3021-3029. View in: PubMed

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. Haematologica. 2017 Sep 07. View in: PubMed

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 Sep; 102(9):e340-e343. View in: PubMed

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. J Clin Pharmacol. 2017 Sep; 57(9):1183-1193. View in: PubMed

Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017 Aug 17; 130(7):943-945. View in: PubMed

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2017 Jul 15; 23(14):3649-3656. View in: PubMed

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017 Jun 22; 129(25):3304-3313. View in: PubMed

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017 Jun 08; 129(23):3051-3058. View in: PubMed

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. J Clin Pharmacol. 2017 Apr 18. View in: PubMed

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017 Apr 14. View in: PubMed

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017 Apr 07. View in: PubMed

Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2017 Jan 20. View in: PubMed

Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2017 Jan; 176(1):86-91. View in: PubMed

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. Pediatr Blood Cancer. 2016 Dec; 63(12):2096-2103. View in: PubMed

Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. Int J Cancer. 2016 Nov 01; 139(9):1930-5. View in: PubMed

Inverse probability weighting estimation of the volume under the ROC surface in the presence of verification bias. Biom J. 2016 Nov; 58(6):1338-1356. View in: PubMed

Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. Int J Cancer. 2016 Nov 1; 139(9):1930-5. View in: PubMed

Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2016 Oct 21. View in: PubMed

A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group. Leukemia. 2016 Oct; 30(10):2077-2080. View in: PubMed

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016 Sep 06; 9(1):82. View in: PubMed

Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. Cancer Med. 2016 Sep; 5(9):2412-6. View in: PubMed

A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 Jul; 57(7):1567-74. View in: PubMed

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood. 2016 Jun 30; 127(26):3424-30. View in: PubMed

Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. J Clin Oncol. 2016 Jun 27. View in: PubMed

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood. 2016 Jun 16; 127(24):3094-8. View in: PubMed

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 May 01; 34(13):1537-43. View in: PubMed

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 May 1; 34(13):1537-43. View in: PubMed

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res. 2016 Apr 15; 76(8):2197-205. View in: PubMed

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 Apr 15; 22(8):1951-7. View in: PubMed

Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador. J Low Genit Tract Dis. 2016 Apr; 20(2):145-50. View in: PubMed

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016 Mar 1; 34(7):747-55. View in: PubMed

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016 Mar 01; 34(7):747-55. View in: PubMed

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res. 2016 04 15; 76(8):2197-205. View in: PubMed

Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016 Jan; 48(1):101. View in: PubMed

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016; 9(1):82. View in: PubMed

Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. Front Genet. 2016; 7:139. View in: PubMed

Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015 Dec 29; 48(1):101. View in: PubMed

Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2015 Dec 20; 33(36):4247-58. View in: PubMed

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. Leukemia. 2015 Dec; 29(12):2424-6. View in: PubMed

Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2015 Dec; 100(12):e496-500. View in: PubMed

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2015 Oct 20; 8:115. View in: PubMed

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Oct; 62(10):1775-81. View in: PubMed

Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus. Open Forum Infect Dis. 2015 Sep; 2(3):ofv101. View in: PubMed

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2015 Jul 15; 21(14):3187-95. View in: PubMed

Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Jul; 62(7):1184-9. View in: PubMed

Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. Cancer Genet. 2015 Jul-Aug; 208(7-8):408-13. View in: PubMed

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Apr; 62(4):629-36. View in: PubMed

Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2015 Jan 15; 125(3):516-24. View in: PubMed

Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. PLoS One. 2015; 10(11):e0143480. View in: PubMed

Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group. PLoS One. 2015; 10(4):e0125290. View in: PubMed

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2015; 8(1):115. View in: PubMed

High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2014 Dec; 55(12):2817-21. View in: PubMed

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014 Oct 9; 124(15):2400-7. View in: PubMed

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014 Oct 09; 124(15):2400-7. View in: PubMed

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60. View in: PubMed

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014 Sep 20; 32(27):3021-32. View in: PubMed

AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15; 120(16):2482-9. View in: PubMed

BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Apr; 61(4):647-52. View in: PubMed

Reducing decision errors in the paired comparison of the diagnostic accuracy of screening tests with Gaussian outcomes. BMC Med Res Methodol. 2014 Mar 05; 14:37. View in: PubMed

Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatr Blood Cancer. 2014 Feb; 61(2):269-75. View in: PubMed

Reducing decision errors in the paired comparison of the diagnostic accuracy of screening tests with Gaussian outcomes. BMC Med Res Methodol. 2014; 14(1):37. View in: PubMed

Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group. Acta Haematol. 2014; 131(3):167-9. View in: PubMed

The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Jan; 61(1):81-8. View in: PubMed

Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013 Dec; 60(12):2073-8. View in: PubMed

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013 Dec 01; 119(23):4170-9. View in: PubMed

Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer. 2013 Dec 01; 119(23):4162-9. View in: PubMed

Accuracy of a home-based device for giving an early estimate of pregnancy duration compared with reference methods. Fertil Steril. 2013 Dec; 100(6):1635-41. e1. View in: PubMed

NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013 Dec; 27(12):2280-8. View in: PubMed

Accuracy of a home-based device for giving an early estimate of pregnancy duration compared with reference methods. Fertil Steril. 2013 Dec; 100(6):1635-1641. e1. View in: PubMed

Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: A Report from the Children's Oncology Group. Cancer. 2013 Dec 1; 119(23):4162-9. View in: PubMed

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013 Dec 1; 119(23):4170-9. View in: PubMed

Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood. 2013 Oct 10; 122(15):2704-13. View in: PubMed

High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol. 2013 Sep; 162(5):670-7. View in: PubMed

Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol. 2013 Aug; 88(8):694-702. View in: PubMed

Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013 Jul; 60(7):1141-7. View in: PubMed

Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Br J Haematol. 2013 Jul; 162(2):250-62. View in: PubMed

Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer. 2013 Jun; 60(6):964-71. View in: PubMed

Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood. 2013 May 2; 121(18):3573-7. View in: PubMed

Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood. 2013 May 02; 121(18):3573-7. View in: PubMed

Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013 Apr; 161(2):192-203. View in: PubMed

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013 Mar 15; 19(6):1620-7. View in: PubMed

Generalization of Youden index for multiple-class classification problems applied to the assessment of externally validated cognition in Parkinson disease screening. Stat Med. 2013 Mar 15; 32(6):995-1003. View in: PubMed

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood. 2013 Feb 14; 121(7):1083-93. View in: PubMed

High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2013 Jan; 54(1):202-4. View in: PubMed

Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatr Blood Cancer. 2012 Nov; 59(5):922-4. View in: PubMed

Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2012 Nov; 97(11):1770-3. View in: PubMed

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 2012 Oct 01; 118(19):4806-14. View in: PubMed

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: A report from the Children's Oncology Group. Cancer. 2012 Oct 1; 118(19):4806-14. View in: PubMed

Extending induced ROC methodology to the functional context. Biostatistics. 2012 Sep; 13(4):594-608. View in: PubMed

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23; 120(8):1581-8. View in: PubMed

Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:37-43. View in: PubMed

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012 Apr 19; 119(16):3705-11. View in: PubMed

Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Apr; 58(4):519-24. View in: PubMed

Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study. Br J Haematol. 2012 Mar; 156(5):649-55. View in: PubMed

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012 Feb 01; 118(3):761-9. View in: PubMed

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer. 2012 Feb 1; 118(3):761-9. View in: PubMed

Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leuk Res. 2012 Jan; 36(1):29-31. View in: PubMed

Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2012 Jan; 34(1):e30-5. View in: PubMed

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011 Dec 22; 118(26):6752-9. View in: PubMed

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011 Dec 22; 118(26):6752-9; quiz 6996. View in: PubMed

A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121). Pediatr Blood Cancer. 2011 Dec 15; 57(7):1230-2. View in: PubMed

Nonparametric Bayesian estimation of the three-way receiver operating characteristic surface. Biom J. 2011 Nov; 53(6):1011-24. View in: PubMed

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 2011 Oct 27; 118(17):4561-6. View in: PubMed

Soluble interleukin-2 receptor a activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2011 Sep; 57(3):398-405. View in: PubMed

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Aug; 57(2):204-9. View in: PubMed

Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15; 57(1):56-62. View in: PubMed

Bias in estimating accuracy of a binary screening test with differential disease verification. Stat Med. 2011 Jul 10; 30(15):1852-64. View in: PubMed

Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood. 2011 Jun 30; 117(26):7102-11. View in: PubMed

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011 Jun 30; 117(26):7007-13. View in: PubMed

Immediate vs. delayed post-abortal copper T 380A IUD insertion in cases over 12 weeks of gestation. Contraception. 2011 Jun; 83(6):522-7. View in: PubMed

Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents. Clin Trials. 2011 Jun; 8(3):247-59. View in: PubMed

Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia. 2011 Jun; 25(6):1039-42. View in: PubMed

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011 May 26; 117(21):5701-9. View in: PubMed

Adequacy of visual inspection with acetic acid in women of advancing age. Int J Gynaecol Obstet. 2011 Apr; 113(1):68-71. View in: PubMed

WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2011 Feb 20; 29(6):704-11. View in: PubMed

Accuracy and cut-off point selection in three-class classification problems using a generalization of the Youden index. Stat Med. 2010 Dec 10; 29(28):2946-55. View in: PubMed

Cytology versus visual inspection with acetic acid among women treated previously with cryotherapy in a low-resource setting. Int J Gynaecol Obstet. 2010 Dec; 111(3):249-52. View in: PubMed

The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Sep; 55(3):414-20. View in: PubMed

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010 Aug 5; 116(5):702-10. View in: PubMed

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010 Aug 05; 116(5):702-10. View in: PubMed

MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug; 55(2):248-53. View in: PubMed

High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2010 Jun 10; 28(17):2831-8. View in: PubMed

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia. 2010 May; 24(5):909-13. View in: PubMed

Diagnostic reproducibility of cervical intraepithelial neoplasia 3 and atrophy in menopausal women on hematoxylin and eosin, Ki-67, and p16 stained slides. J Low Genit Tract Dis. 2010 Apr; 14(2):108-12. View in: PubMed

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010 Mar 25; 115(12):2372-9. View in: PubMed

Estimates of sensitivity and specificity can be biased when reporting the results of the second test in a screening trial conducted in series. BMC Med Res Methodol. 2010 Jan 11; 10:3. View in: PubMed

Digital assessment of the reproductive tract versus colposcopy for directing biopsies in women with abnormal Pap smears. J Low Genit Tract Dis. 2010 Jan; 14(1):5-10. View in: PubMed

Estimates of sensitivity and specificity can be biased when reporting the results of the second test in a screening trial conducted in series. BMC Med Res Methodol. 2010; 10:3. View in: PubMed

WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Dec; 53(6):1136-9. View in: PubMed

Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer. 2009 Dec; 53(6):1005-10. View in: PubMed

A receiver operating characteristic analysis approach for the assessment of the separation of female Mediterranean fruit fly (Diptera: Tephritidae) oviposition distributions. J Econ Entomol. 2009 Oct; 102(5):1985-91. View in: PubMed

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009 Sep 17; 114(12):2489-96. View in: PubMed

Effect of tidal volume in children with acute hypoxemic respiratory failure. Intensive Care Med. 2009 Aug; 35(8):1428-37. View in: PubMed

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009 Jun 25; 113(26):6558-66. View in: PubMed

Comparing accuracy in an unpaired post-market device study with incomplete disease assessment. Biom J. 2009 Jun; 51(3):491-503. View in: PubMed

Adolescent comprehension of emergency contraception in New York City. Obstet Gynecol. 2009 Apr; 113(4):840-4. View in: PubMed

A comparison of tests for restricted orderings in the three-class case. Stat Med. 2009 Mar 30; 28(7):1144-58. View in: PubMed

Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009 Mar 1; 115(5):1100-8. View in: PubMed

Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009 Mar 01; 115(5):1100-8. View in: PubMed

Disseminated intravascular coagulation score is associated with mortality for children with shock. Intensive Care Med. 2009 Feb; 35(2):327-33. View in: PubMed

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb; 144(3):388-94. View in: PubMed

Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Stat Biopharm Res. 2009 Feb 1; 1(1):18-25. View in: PubMed

Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Stat Biopharm Res. 2009 Feb 01; 1(1):18-25. View in: PubMed

Bias in trials comparing paired continuous tests can cause researchers to choose the wrong screening modality. BMC Med Res Methodol. 2009 Jan 20; 9:4. View in: PubMed

Bias in trials comparing paired continuous tests can cause researchers to choose the wrong screening modality. BMC Med Res Methodol. 2009; 9:4. View in: PubMed

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5797-801. View in: PubMed

FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 01; 14(23):7896-9. View in: PubMed

Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Dec; 51(6):784-6. View in: PubMed

FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1; 14(23):7896-9. View in: PubMed

DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer. 2008 Oct 23; 7:81. View in: PubMed

Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 2008 May 15; 111(10):4930-3. View in: PubMed

Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2008 May 10; 26(14):2390-3295. View in: PubMed

A modified sign test for comparing paired ROC curves. Biostatistics. 2008 Apr; 9(2):364-72. View in: PubMed

DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb; 22(2):265-72. View in: PubMed

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008 Feb 01; 111(3):1044-53. View in: PubMed

The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. Am J Clin Pathol. 2008 Feb; 129(2):193-201. View in: PubMed

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008 Feb 1; 111(3):1044-53. View in: PubMed

Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatr Blood Cancer. 2008 Jan; 50(1):9-16. View in: PubMed

DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer. 2008; 7:81. View in: PubMed

Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007 Nov 15; 110(10):3532-9. View in: PubMed

Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplant. 2007 Aug; 40(4):313-8. View in: PubMed

The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007 Aug 01; 110(3):979-85. View in: PubMed

The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007 Aug 1; 110(3):979-85. View in: PubMed

Comparison of ROC umbrella volumes with an application to the assessment of lung cancer diagnostic markers. Biom J. 2007 Aug; 49(5):654-64. View in: PubMed

Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Jul; 49(1):17-22. View in: PubMed

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007 Jun 01; 109(11):4641-7. View in: PubMed

ROC graphs for assessing the ability of a diagnostic marker to detect three disease classes with an umbrella ordering. Biometrics. 2007 Jun; 63(2):603-9. View in: PubMed

Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007 Jun 1; 109(11):4641-7. View in: PubMed

Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group. J Clin Oncol. 2007 May 20; 25(15):2070-7. View in: PubMed

Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood. 2007 Mar 15; 109(6):2314-21. View in: PubMed

Development and evaluation of classifiers. Methods Mol Biol. 2007; 404:89-116. View in: PubMed

Statistical methods for evaluating DNA methylation as a marker for early detection or prognosis. Dis Markers. 2007; 23(1-2):113-20. View in: PubMed

Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006 Dec 1; 108(12):3654-61. View in: PubMed

Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006 Dec 01; 108(12):3654-61. View in: PubMed

FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood. 2006 Oct 15; 108(8):2764-9. View in: PubMed

Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2006 Jul 01; 108(1):74-80. View in: PubMed

Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2006 Jul 1; 108(1):74-80. View in: PubMed

Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood. 2006 Jul 1; 108(1):400; author reply 400-1. View in: PubMed

Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood. 2006 Jul 01; 108(1):400; author reply 400-1. View in: PubMed

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7. View in: PubMed

A novel design for estimating relative accuracy of screening tests when complete disease verification is not feasible. Biometrics. 2006 Jun; 62(2):605-12. View in: PubMed

Using the ROC curve for gauging treatment effect in clinical trials. Stat Med. 2006 Feb 28; 25(4):575-90. View in: PubMed

XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. Blood. 2006 Jan 01; 107(1):39-45. View in: PubMed

XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. Blood. 2006 Jan 1; 107(1):39-45. View in: PubMed

Standards for reporting prognostic tumor marker studies. J Clin Oncol. 2005 Dec 20; 23(36):9053-4. View in: PubMed

Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol. 2005 Dec 20; 23(36):9172-8. View in: PubMed

Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005 Dec; 19(12):2054-62. View in: PubMed

Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia. 2005 Jun; 19(6):965-70. View in: PubMed

Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests. Stat Med. 2005 Feb 15; 24(3):403-17. View in: PubMed

Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005 Jan 12; 293(2):203-11. View in: PubMed

Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood. 2004 Nov 15; 104(10):3058-63. View in: PubMed

PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia. 2004 Nov; 18(11):1831-4. View in: PubMed

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood. 2004 Sep 15; 104(6):1841-9. View in: PubMed

Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004 May 15; 103(10):3655-61. View in: PubMed

Small sample estimation of relative accuracy for binary screening tests. Stat Med. 2004 Jan 15; 23(1):21-34. View in: PubMed

Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol. 2004 Jan 01; 22(1):150-6. View in: PubMed

Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol. 2004 Jan 1; 22(1):150-6. View in: PubMed

Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2003 Oct; 25(10):760-8. View in: PubMed

Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003 Sep 15; 21(18):3415-22. View in: PubMed

Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003 Aug 15; 102(4):1474-9. View in: PubMed

Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2003 Aug; 25(8):594-600. View in: PubMed

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003 Aug 1; 21(15):2940-7. View in: PubMed

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003 Aug 01; 21(15):2940-7. View in: PubMed

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003 May 1; 101(9):3398-406. View in: PubMed

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003 May 01; 101(9):3398-406. View in: PubMed

Estimating disease prevalence in two-phase studies. Biostatistics. 2003 Apr; 4(2):313-26. View in: PubMed

Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2002 Nov; 24(8):627-35. View in: PubMed

Distribution-free ROC analysis using binary regression techniques. Biostatistics. 2002 Sep; 3(3):421-32. View in: PubMed

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American view. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? --an American view. Br J Haematol. 2002 Aug; 118(2):378-84. View in: PubMed

Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002 Jul 15; 100(2):427-34. View in: PubMed

Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia. 2002 Apr; 16(4):601-7. View in: PubMed

Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat Med. 2002 Mar 30; 21(6):835-52. View in: PubMed

Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol. 2002 Jan 15; 20(2):434-40. View in: PubMed

Comparing disease screening tests when true disease status is ascertained only for screen positives. Biostatistics. 2001 Sep; 2(3):249-60. View in: PubMed

Using a combination of reference tests to assess the accuracy of a new diagnostic test. Stat Med. 1999 Nov 30; 18(22):2987-3003. View in: PubMed

Powered bySC CTSI